Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 17/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26614828 | 1.00 | GPR55 (0.52) | GPR55PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3559049 | 0.82 | PLK1 (0.45) | GPR55 | |
| SCHEMBL17560899 | 0.80 | ATP1A1 (0.49) | GPR55 | |
| SCHEMBL30639788 | 0.78 | GPR55 (0.49) | GPR55PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL26614694 | 0.78 | GPR55 (0.49) | GPR55PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL26614692 | 0.78 | GPR55 (0.49) | GPR55PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20575148 | 0.77 | HTR7 (0.53) | GPR55NTRK1 | |
| SCHEMBL20575147 | 0.77 | HTR7 (0.53) | GPR55NTRK1 | |
| SCHEMBL3515072 | 0.77 | AURKA (0.52) | GPR55NTRK1 | |
| SCHEMBL3557473 | 0.77 | AURKA (0.52) | GPR55NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4514788-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-1878767-B | Azole-based kinase inhibitors | CYTOPIA RES PTY LTD | 2010-05-05 | — | — | CN | disclosed |
| CN-1878767-A | Azole-based kinase inhibitors | CYTOPIA RES PTY LTD (AU) | 2006-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | GPR55 1/4885PSEN1 1973/4885PSEN2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.